Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-[12-(1H-imidazol-1-yl)dodecanoyl]-L-leucine is a synthetic small molecule belonging to the class of leucine derivatives, specifically an L-peptide linking compound. It features a dodecanoic acid chain with an imidazole group at the omega position, conjugated to L-leucine. This compound has been studied as an inhibitor of cytochrome P450 BM3 (CYP102A1), a bacterial P450 enzyme from Bacillus megaterium. Structural studies show it binds to the heme domain of P450BM3 and acts as a more potent inhibitor than parent omega-imidazolyl fatty acids, likely due to its unique interaction with the enzyme's active site. Its pharmacological action in humans is unknown and it has not been approved for any clinical use[6][9][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-[12-(1H-imidazol-1-yl)dodecanoyl]-L-leucine.